# Frederik Husum Mårup

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/frederik-husum-marup/

## Facts

| Field | Value |
| --- | --- |
| Citations | 270 |
| Field | Diabetes Treatment and Management |
| h-index | 4 |
| i10-index | 3 |
| Last Known Institution | Aarhus University |
| OpenAlex ID | https://openalex.org/A5072104235 |
| ORCID iD | 0000-0002-6367-338X |
| Works | 10 |

## Researcher papers

- [Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease](https://scholariq.org/papers/brain-inflammation-accompanies-amyloid-in-the-majority-of-mild-cognitive/)
- [Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial](https://scholariq.org/papers/additive-effects-of-dapagliflozin-and-finerenone-on-albuminuria-in-non-diabetic/)
- [Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD](https://scholariq.org/papers/can-patiromer-allow-for-intensified-renin-angiotensin-aldosterone-system/)
- [<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial](https://scholariq.org/papers/scp-sglt2-scp-inhibition-improves-endothelium-independent-vasodilatory-function/)
- [#3068 POTASSIUM LEVELS AND EGFR DO NOT PREDICT SEVERE HYPERKALEMIA FOLLOWING SPIRONOLACTONE INTRODUCTION IN PATIENTS WITH CKD AT HIGH RISK OF HYPERKALEMIA](https://scholariq.org/papers/3068-potassium-levels-and-egfr-do-not-predict-severe-hyperkalemia-following/)
- [#6650 SGLT2-INHIBITION IMPROVES VASCULAR FUNCTION IN TYPE 2 DIABETES: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED CROSSOVER TRIAL](https://scholariq.org/papers/6650-sglt2-inhibition-improves-vascular-function-in-type-2-diabetes-a-double/)
- [Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial](https://scholariq.org/papers/patiromer-to-reduce-albuminuria-through-increased-renin-angiotensin-aldosterone/)
- [SGLT2 Inhibition Improves Vascular Function in Patients with Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial](https://scholariq.org/papers/sglt2-inhibition-improves-vascular-function-in-patients-with-type-2-diabetes-a/)
- [Author response for "&lt;scp&gt;SGLT2&lt;/scp&gt; inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial"](https://scholariq.org/papers/author-response-for-and-lt-scp-and-gt-sglt2-and-lt-scp-and-gt-inhibition/)
- [Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis](https://scholariq.org/papers/mechanisms-of-sglt-inhibitor-action-and-physiological-mediators-systematic/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Potassium and Related Disorders](https://scholariq.org/topics/potassium-and-related-disorders/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Nitric Oxide and Endothelin Effects](https://scholariq.org/topics/nitric-oxide-and-endothelin-effects/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Researcher university

- [Aarhus University](https://scholariq.org/institutions/aarhus-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.